Adlai Nortye Ltd. (NASDAQ:ANL) Short Interest Up 48.8% in March

Adlai Nortye Ltd. (NASDAQ:ANL) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 6,400 shares, a growth of 48.8% from the March 15th total of 4,300 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average trading volume of 6,900 shares, the short-interest ratio is currently 0.9 days.

Adlai Nortye Stock Down 10.5 %

ANL opened at $1.71 on Friday. Adlai Nortye has a 52 week low of $1.69 and a 52 week high of $15.55. The business has a 50 day moving average price of $2.16 and a two-hundred day moving average price of $2.20.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.